(Reuters) – Eli Lilly and Co’s cancer drug Cyramza helped patients with liver cancer live longer, meeting the main goal of a late-stage trial, four years after failing a prior study.
https://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.png00Reuters: Health Newshttps://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.pngReuters: Health News2018-04-04 13:21:442018-04-04 16:34:40Lilly’s Cyramza succeeds in late-stage liver cancer trial